Scholarlink

Purpose of Review <p>We intend to establish broad clinical subgroups of patients and match them to a more tailored approach with improved clinical outcomes.</p> Recent Findings <p>Patient experience over the past four decades and investigative initiatives such as The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) have led to the development of four broad categories of IC/BPS patients: bladder-centric (which is further sub-divided into those with Hunner lesion disease (HLD) and those without (IC/BPS)); widespread/centralized pain; and myofascial pelvic floor tenderness. Other systems of patient categorization, such as UPOINT, now INPUT, highlight the complexities of patient assessment.</p> <p>Reanalysis of previous failed clinical trials and common sense suggests that matching the therapy's mechanism of action to the patient’s phenotype may yield better therapeutic outcomes.</p> Summary <p>Although the IC/BPS population is known to be phenotypically heterogeneous, therapeutic approaches afforded by most current guidelines have been relatively rigid, only accounting for those patients with and without Hunner lesions. Segregating the IC/BPS population further into distinct phenotypic groups that may respond to targeted therapy is relatively simplistic but represents an essential first step toward precision care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Interstitial Cystitis/Bladder Pain Syndrome: Matching Therapies to the Patient

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月13日

查看全文
  • Jennifer Fariello Moldwin,
  • Robert M. Moldwin

摘要

Purpose of Review

We intend to establish broad clinical subgroups of patients and match them to a more tailored approach with improved clinical outcomes.

Recent Findings

Patient experience over the past four decades and investigative initiatives such as The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) have led to the development of four broad categories of IC/BPS patients: bladder-centric (which is further sub-divided into those with Hunner lesion disease (HLD) and those without (IC/BPS)); widespread/centralized pain; and myofascial pelvic floor tenderness. Other systems of patient categorization, such as UPOINT, now INPUT, highlight the complexities of patient assessment.

Reanalysis of previous failed clinical trials and common sense suggests that matching the therapy's mechanism of action to the patient’s phenotype may yield better therapeutic outcomes.

Summary

Although the IC/BPS population is known to be phenotypically heterogeneous, therapeutic approaches afforded by most current guidelines have been relatively rigid, only accounting for those patients with and without Hunner lesions. Segregating the IC/BPS population further into distinct phenotypic groups that may respond to targeted therapy is relatively simplistic but represents an essential first step toward precision care.